CL2017001823A1 - Compuestos para mejorar el empalme de marn - Google Patents

Compuestos para mejorar el empalme de marn

Info

Publication number
CL2017001823A1
CL2017001823A1 CL2017001823A CL2017001823A CL2017001823A1 CL 2017001823 A1 CL2017001823 A1 CL 2017001823A1 CL 2017001823 A CL2017001823 A CL 2017001823A CL 2017001823 A CL2017001823 A CL 2017001823A CL 2017001823 A1 CL2017001823 A1 CL 2017001823A1
Authority
CL
Chile
Prior art keywords
compounds
marn
improve
splicing
methods
Prior art date
Application number
CL2017001823A
Other languages
English (en)
Inventor
Wei Zhang
Juan MARUGAN
Susan A Slaugenhaupt
Graham Johnson
William D Paquette
Original Assignee
Massachusetts Gen Hospital
United States Dept Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital, United States Dept Of Health And Human Services filed Critical Massachusetts Gen Hospital
Publication of CL2017001823A1 publication Critical patent/CL2017001823A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

<p>SE PROPORCIONAN COMPUESTOS EFICACES PARA MEJORAR EL EMPALME DE MARN EN UNA CÉLULA. COMPUESTOS EJEMPLARES QUE SE PROPORCIONAN EN LA PRESENTE SON EFICACES PARA MEJORAR EL EMPALME DE MARN EN GENES QUE COMPRENDEN AL MENOS UN EXÓN QUE TERMINA EN LA SECUENCIA DE NUCLEÓTIDOS CAA. SE PROPORCIONAN MÉTODOS PARA PREPARAR LOS COMPUESTOS Y MÉTODOS PARA TRATAR ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL.</p>
CL2017001823A 2015-01-16 2017-07-13 Compuestos para mejorar el empalme de marn CL2017001823A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562104547P 2015-01-16 2015-01-16
US201562180380P 2015-06-16 2015-06-16

Publications (1)

Publication Number Publication Date
CL2017001823A1 true CL2017001823A1 (es) 2018-04-13

Family

ID=56406434

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017001823A CL2017001823A1 (es) 2015-01-16 2017-07-13 Compuestos para mejorar el empalme de marn
CL2019002167A CL2019002167A1 (es) 2015-01-16 2019-08-01 Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019002167A CL2019002167A1 (es) 2015-01-16 2019-08-01 Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.)

Country Status (16)

Country Link
US (3) US10676475B2 (es)
EP (2) EP3244891B9 (es)
AU (2) AU2016206589B2 (es)
BR (1) BR112017015019A2 (es)
CA (2) CA2973949C (es)
CL (2) CL2017001823A1 (es)
DK (1) DK3244891T3 (es)
EA (1) EA037663B1 (es)
ES (1) ES2928714T3 (es)
HU (1) HUE059891T2 (es)
IL (2) IL253291B (es)
MX (2) MX2017009295A (es)
PL (1) PL3244891T3 (es)
PT (1) PT3244891T (es)
TW (2) TWI727939B (es)
WO (1) WO2016115434A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2973949C (en) * 2015-01-16 2023-07-11 The General Hospital Corporation Compounds for improving mrna splicing
IL294124B2 (en) 2015-12-10 2024-02-01 Ptc Therapeutics Inc Methods for treating huntington's disease
EP3528816A4 (en) * 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
WO2018151326A1 (ja) 2017-02-20 2018-08-23 国立大学法人京都大学 スプライシング異常に起因する遺伝性疾病のための医薬組成物及び治療方法
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
MX2020009957A (es) 2018-03-27 2021-01-15 Ptc Therapeutics Inc Compuestos para el tratamiento de enfermedad de hungtinton.
PL3814357T3 (pl) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
EP3814345B8 (en) 2018-06-27 2024-10-30 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
EP3861000A1 (en) * 2018-10-01 2021-08-11 Genzyme Corporation Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
MX2021010319A (es) * 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos biciclicos de heteroarilo y usos de estos.
MX2021010323A (es) * 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos bicíclicos de heterociclilo y usos de este.
WO2020231977A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
CA3156359A1 (en) 2019-11-08 2021-05-14 Adrian Liam Gill Bicyclic heteroaryl compounds and uses thereof
CN115209955A (zh) * 2019-12-12 2022-10-18 Ptc医疗公司 治疗家族性自主神经功能障碍的化合物
EP4084796A1 (en) 2020-01-02 2022-11-09 The General Hospital Corporation Rna splicing modulation
CN111777612B (zh) * 2020-06-05 2022-04-19 广东达元绿洲食品安全科技股份有限公司 一种6-苄基腺嘌呤半抗原、人工抗原及其在免疫检测中的应用
EP4288441A4 (en) * 2021-02-05 2024-12-11 PTC Therapeutics, Inc. Methods for treating spinocerebellar ataxia type 3
CN113151296B (zh) * 2021-03-22 2022-09-13 云南中烟工业有限责任公司 一种烟草热激蛋白相关的基因及其应用
EP4398987A4 (en) 2021-09-07 2025-07-09 Ptc Therapeutics Inc METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES
CN118251225A (zh) 2021-09-07 2024-06-25 Ptc医疗公司 治疗神经退行性疾病的方法
WO2025227159A1 (en) * 2024-04-26 2025-10-30 The General Hospital Corporation Gene editing treatment for correcting splicing defect in familial dysautonomia

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3041340A (en) 1962-06-26 Method of preparing substituted
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB9613736D0 (en) 1996-07-01 1996-09-04 Hancock Tony Transport cradle for a skid-supported helicopter
US6933280B2 (en) * 1996-10-08 2005-08-23 Gerardo Castillo Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
TR200002482T2 (tr) 1998-02-26 2002-10-21 Aventis Pharmaceuticals Inc. 6,9-Diikameli 2-(Trans-(4-Aminosiklohekzil) Amino)Pürinler
CZ294535B6 (cs) 2001-08-02 2005-01-12 Ústav Experimentální Botaniky Avčr Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
WO2005003290A2 (en) 2002-09-10 2005-01-13 The Regents Of The University Of California Methods and devices for determining a cell characteristic, and applications employing same
CA2540681C (en) 2003-10-03 2014-08-12 The General Hospital Corporation Methods for altering mrna splicing and treating familial dysautonomia and other mechanistically related disorders
US20050239806A1 (en) * 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
KR101450535B1 (ko) * 2006-02-02 2014-10-14 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ１ 활성화 효소의 억제제
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
DK2137186T3 (en) * 2007-03-23 2016-04-18 Amgen Inc Heterocyclic compounds and their uses
GB0706632D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
AU2009238590A1 (en) * 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
BRPI0919488A2 (pt) 2008-09-30 2015-12-01 Astrazeneca Ab composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
TW201041892A (en) 2009-02-09 2010-12-01 Supergen Inc Pyrrolopyrimidinyl Axl kinase inhibitors
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
WO2011041655A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Quinazolin-4-amine derivatives; and methods of use
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
US20130072506A1 (en) 2011-09-16 2013-03-21 Lenka ZAHAJSKA 6,8-disubstituted purine compositions
HK1201514A1 (en) 2011-11-18 2015-09-04 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
CZ306894B6 (cs) 2013-02-08 2017-08-30 Univerzita PalackĂ©ho v Olomouci 2-Substituované-6-biarylmethylamino-9-cyklopentyl-9H-purinové deriváty, jejich použití jako léčiva a farmaceutické přípravky tyto sloučeniny obsahující
WO2014124458A1 (en) 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
US9938279B2 (en) 2013-04-09 2018-04-10 Energenesis Biomedical Co., Ltd Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)
US9879014B2 (en) * 2013-07-12 2018-01-30 Kyoto University Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease
ES2919024T3 (es) 2014-02-11 2022-07-21 Mitokinin Inc Composiciones y procedimientos que utilizan las mismas para el tratamiento de enfermedades neurodegenerativas y mitocondriales
US10519160B2 (en) 2014-07-18 2019-12-31 The General Hospital Corporation Imaging agents for neural flux
CA2973949C (en) * 2015-01-16 2023-07-11 The General Hospital Corporation Compounds for improving mrna splicing

Also Published As

Publication number Publication date
AU2020277224A1 (en) 2020-12-24
EP4115882A1 (en) 2023-01-11
EP3244891A4 (en) 2018-12-19
TWI727939B (zh) 2021-05-21
BR112017015019A2 (pt) 2018-01-30
AU2016206589B2 (en) 2020-09-10
US10676475B2 (en) 2020-06-09
CL2019002167A1 (es) 2019-12-13
ES2928714T9 (es) 2022-11-29
CA2973949A1 (en) 2016-07-21
ES2928714T3 (es) 2022-11-22
MX2017009295A (es) 2018-03-07
TW201636341A (zh) 2016-10-16
IL270945A (en) 2020-01-30
EP3244891B9 (en) 2022-11-16
PL3244891T3 (pl) 2022-12-27
PT3244891T (pt) 2022-10-20
CA2973949C (en) 2023-07-11
WO2016115434A1 (en) 2016-07-21
TW202204345A (zh) 2022-02-01
IL253291B (en) 2021-10-31
AU2020277224B2 (en) 2022-12-22
EP3244891A1 (en) 2017-11-22
EA037663B1 (ru) 2021-04-28
DK3244891T3 (da) 2022-10-24
AU2016206589A1 (en) 2017-07-27
IL253291A0 (en) 2017-09-28
CA3199430A1 (en) 2016-07-21
US11702417B2 (en) 2023-07-18
EP3244891B1 (en) 2022-07-20
US20230279007A1 (en) 2023-09-07
EA201791624A1 (ru) 2018-06-29
US20200283441A1 (en) 2020-09-10
MX2022015737A (es) 2023-01-18
HUE059891T2 (hu) 2023-01-28
US20180118748A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
CL2017001823A1 (es) Compuestos para mejorar el empalme de marn
IL287889A (en) Administration of engineered t cells for treatment of cancers in the central nervous system
CY1125338T1 (el) Λιποκατιονικα δενδριμερη και χρησεις εξ αυτων
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
MX2021009673A (es) Moduladores de ror-gamma.
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CO2017011484A2 (es) Inhibidores de bromodominio
UY36748A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen
CO2017007335A2 (es) Supresión del gen de la huntingtina inducida por la arni
MX2017006283A (es) Peptidos macrociclicos utiles como inmunomoduladores.
MX2017014375A (es) Moduladores del ccr2.
MX2019001672A (es) Composiciones de poxvirus quiméricos y usos de las mismas.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2017001046A1 (es) Inhibidoes del bromodominio
UY36747A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
MX2016001587A (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
MX2018000511A (es) Derivados de fenoximetilo.
UY36749A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen
GT201700062A (es) N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b
MX2018004050A (es) Inhibidores marcados con 18f mejorados del antigeno prostatico especifico de membrana (psma) y su uso como agentes de formacion de imagenes para el cancer de prostata.
CO2017005038A2 (es) Composicones y métodos de tratamiento con profármacos de tizoxanida, un análogo o sal de la misma
CO2017000950A2 (es) Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos
CL2017000040A1 (es) Inhibidores de aldosterona sintasa.
AR113543A2 (es) Ésteres de oxaborol y sus usos